Cargando…
In Vitro Activity of Ceftolozane-Tazobactam vs. Antimicrobial Non-Susceptible Pseudomonas aeruginosa Clinical Isolates Obtained from Across Canada as Part of the CANWARD Study, 2008–2016
BACKGROUND: Ceftolozane-tazobactam (C/T) is a novel β-lactam β-lactamase inhibitor combination with a broad spectrum of activity that includes Pseudomonas aeruginosa. The purpose of this study was to evaluate the in vitro activity of C/T and relevant comparators vs. a large collection of antimicrobi...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630865/ http://dx.doi.org/10.1093/ofid/ofx163.913 |
_version_ | 1783269311799885824 |
---|---|
author | Walkty, Andrew Adam, Heather J Baxter, Melanie Lagace-Wiens, Philippe Karlowsky, James Hoban, Daryl Zhanel, George |
author_facet | Walkty, Andrew Adam, Heather J Baxter, Melanie Lagace-Wiens, Philippe Karlowsky, James Hoban, Daryl Zhanel, George |
author_sort | Walkty, Andrew |
collection | PubMed |
description | BACKGROUND: Ceftolozane-tazobactam (C/T) is a novel β-lactam β-lactamase inhibitor combination with a broad spectrum of activity that includes Pseudomonas aeruginosa. The purpose of this study was to evaluate the in vitro activity of C/T and relevant comparators vs. a large collection of antimicrobial non-susceptible (NS) P. aeruginosa clinical isolates obtained from patients across Canada (CANWARD, 2008–2016). METHODS: From January 2008 to December 2016, inclusive, 12 to 15 sentinel hospitals across Canada submitted clinical isolates from patients attending ERs, medical and surgical wards, hospital clinics, and ICUs (CANWARD). Each center was asked to annually submit clinical isolates (consecutive, one per patient/infection site) from blood, respiratory, urine, and wound infections. Susceptibility testing was performed using broth microdilution as described by CLSI. Multidrug-resistant (MDR) P. aeruginosa were defined as isolates that tested NS to at least one antimicrobial from ≥3 classes. Extensively drug-resistant (XDR) P. aeruginosa were defined as isolates that tested NS to at least one antimicrobial from ≥5 classes. RESULTS: 3229 P. aeruginosa isolates were obtained as a part of CANWARD. The in vitro activity of C/T and relevant comparators is presented below. CONCLUSION: C/T demonstrated excellent in vitro activity vs. antimicrobial NS P. aeruginosa clinical isolates, including MDR, XDR, and meropenem NS subsets. It may prove useful in the treatment of infections caused by these organisms. DISCLOSURES: D. Hoban, Abbott: Research relationship, Research support Achaogen: Research relationship, Research support Astellas: Research relationship, Research support Merck Canada: Research relationship, Research support Merck USA: Research relationship, Research support Paratek Pharma: Research relationship, Research support Pharmascience: Research relationship, Research support Sunovion: Research relationship, Research support Tetraphase: Research relationship, Research support The Medicines Co.: Research relationship, Research support Zoetis: Research relationship, Research support; G. Zhanel, Achaogen: Research relationship, Research support Astellas: Research relationship, Research support Merck Canada: Research relationship, Research support Merck USA: Research relationship, Research support Paratek Pharma: Research relationship, Research support Pharmascience: Research relationship, Research support Sunovion: Research relationship, Research support Tetraphase: Research relationship, Research support The Medicines Co.: Research relationship, Research support Zoetis: Research relationship, Research support |
format | Online Article Text |
id | pubmed-5630865 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-56308652017-11-07 In Vitro Activity of Ceftolozane-Tazobactam vs. Antimicrobial Non-Susceptible Pseudomonas aeruginosa Clinical Isolates Obtained from Across Canada as Part of the CANWARD Study, 2008–2016 Walkty, Andrew Adam, Heather J Baxter, Melanie Lagace-Wiens, Philippe Karlowsky, James Hoban, Daryl Zhanel, George Open Forum Infect Dis Abstracts BACKGROUND: Ceftolozane-tazobactam (C/T) is a novel β-lactam β-lactamase inhibitor combination with a broad spectrum of activity that includes Pseudomonas aeruginosa. The purpose of this study was to evaluate the in vitro activity of C/T and relevant comparators vs. a large collection of antimicrobial non-susceptible (NS) P. aeruginosa clinical isolates obtained from patients across Canada (CANWARD, 2008–2016). METHODS: From January 2008 to December 2016, inclusive, 12 to 15 sentinel hospitals across Canada submitted clinical isolates from patients attending ERs, medical and surgical wards, hospital clinics, and ICUs (CANWARD). Each center was asked to annually submit clinical isolates (consecutive, one per patient/infection site) from blood, respiratory, urine, and wound infections. Susceptibility testing was performed using broth microdilution as described by CLSI. Multidrug-resistant (MDR) P. aeruginosa were defined as isolates that tested NS to at least one antimicrobial from ≥3 classes. Extensively drug-resistant (XDR) P. aeruginosa were defined as isolates that tested NS to at least one antimicrobial from ≥5 classes. RESULTS: 3229 P. aeruginosa isolates were obtained as a part of CANWARD. The in vitro activity of C/T and relevant comparators is presented below. CONCLUSION: C/T demonstrated excellent in vitro activity vs. antimicrobial NS P. aeruginosa clinical isolates, including MDR, XDR, and meropenem NS subsets. It may prove useful in the treatment of infections caused by these organisms. DISCLOSURES: D. Hoban, Abbott: Research relationship, Research support Achaogen: Research relationship, Research support Astellas: Research relationship, Research support Merck Canada: Research relationship, Research support Merck USA: Research relationship, Research support Paratek Pharma: Research relationship, Research support Pharmascience: Research relationship, Research support Sunovion: Research relationship, Research support Tetraphase: Research relationship, Research support The Medicines Co.: Research relationship, Research support Zoetis: Research relationship, Research support; G. Zhanel, Achaogen: Research relationship, Research support Astellas: Research relationship, Research support Merck Canada: Research relationship, Research support Merck USA: Research relationship, Research support Paratek Pharma: Research relationship, Research support Pharmascience: Research relationship, Research support Sunovion: Research relationship, Research support Tetraphase: Research relationship, Research support The Medicines Co.: Research relationship, Research support Zoetis: Research relationship, Research support Oxford University Press 2017-10-04 /pmc/articles/PMC5630865/ http://dx.doi.org/10.1093/ofid/ofx163.913 Text en © The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstracts Walkty, Andrew Adam, Heather J Baxter, Melanie Lagace-Wiens, Philippe Karlowsky, James Hoban, Daryl Zhanel, George In Vitro Activity of Ceftolozane-Tazobactam vs. Antimicrobial Non-Susceptible Pseudomonas aeruginosa Clinical Isolates Obtained from Across Canada as Part of the CANWARD Study, 2008–2016 |
title | In Vitro Activity of Ceftolozane-Tazobactam vs. Antimicrobial Non-Susceptible Pseudomonas aeruginosa Clinical Isolates Obtained from Across Canada as Part of the CANWARD Study, 2008–2016 |
title_full | In Vitro Activity of Ceftolozane-Tazobactam vs. Antimicrobial Non-Susceptible Pseudomonas aeruginosa Clinical Isolates Obtained from Across Canada as Part of the CANWARD Study, 2008–2016 |
title_fullStr | In Vitro Activity of Ceftolozane-Tazobactam vs. Antimicrobial Non-Susceptible Pseudomonas aeruginosa Clinical Isolates Obtained from Across Canada as Part of the CANWARD Study, 2008–2016 |
title_full_unstemmed | In Vitro Activity of Ceftolozane-Tazobactam vs. Antimicrobial Non-Susceptible Pseudomonas aeruginosa Clinical Isolates Obtained from Across Canada as Part of the CANWARD Study, 2008–2016 |
title_short | In Vitro Activity of Ceftolozane-Tazobactam vs. Antimicrobial Non-Susceptible Pseudomonas aeruginosa Clinical Isolates Obtained from Across Canada as Part of the CANWARD Study, 2008–2016 |
title_sort | in vitro activity of ceftolozane-tazobactam vs. antimicrobial non-susceptible pseudomonas aeruginosa clinical isolates obtained from across canada as part of the canward study, 2008–2016 |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630865/ http://dx.doi.org/10.1093/ofid/ofx163.913 |
work_keys_str_mv | AT walktyandrew invitroactivityofceftolozanetazobactamvsantimicrobialnonsusceptiblepseudomonasaeruginosaclinicalisolatesobtainedfromacrosscanadaaspartofthecanwardstudy20082016 AT adamheatherj invitroactivityofceftolozanetazobactamvsantimicrobialnonsusceptiblepseudomonasaeruginosaclinicalisolatesobtainedfromacrosscanadaaspartofthecanwardstudy20082016 AT baxtermelanie invitroactivityofceftolozanetazobactamvsantimicrobialnonsusceptiblepseudomonasaeruginosaclinicalisolatesobtainedfromacrosscanadaaspartofthecanwardstudy20082016 AT lagacewiensphilippe invitroactivityofceftolozanetazobactamvsantimicrobialnonsusceptiblepseudomonasaeruginosaclinicalisolatesobtainedfromacrosscanadaaspartofthecanwardstudy20082016 AT karlowskyjames invitroactivityofceftolozanetazobactamvsantimicrobialnonsusceptiblepseudomonasaeruginosaclinicalisolatesobtainedfromacrosscanadaaspartofthecanwardstudy20082016 AT hobandaryl invitroactivityofceftolozanetazobactamvsantimicrobialnonsusceptiblepseudomonasaeruginosaclinicalisolatesobtainedfromacrosscanadaaspartofthecanwardstudy20082016 AT zhanelgeorge invitroactivityofceftolozanetazobactamvsantimicrobialnonsusceptiblepseudomonasaeruginosaclinicalisolatesobtainedfromacrosscanadaaspartofthecanwardstudy20082016 |